Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice

被引:38
|
作者
Li, Xia [1 ]
Risbrough, Victoria B. [1 ,4 ]
Cates-Gatto, Chelsea [2 ]
Kaczanowska, Katarzyna [3 ]
Finn, M. G. [3 ]
Roberts, Amanda J. [2 ]
Markou, Athina [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA
[2] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[4] Vet Affairs Ctr Excellence Stress & Mental Hlth, La Jolla, CA USA
基金
美国国家卫生研究院;
关键词
GABA(B) receptor; Positive allosteric modulator; Anxiety; Learning; Memory; GAMMA-AMINOBUTYRIC-ACID; VOGEL CONFLICT TEST; ELEVATED PLUS-MAZE; ALLOSTERIC MODULATOR; ANIMAL-MODELS; MOTIVATIONAL PROPERTIES; WORKING-MEMORY; SPATIAL MEMORY; WATER MAZE; GS39783;
D O I
10.1016/j.neuropharm.2013.01.018
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
gamma-Arninobutyric acid B (GABA(B)) receptor activation is a potential therapeutic approach for the treatment of drug addiction, pain, anxiety, and depression. However, full agonists of this receptor induce side-effects, such as sedation, muscle relaxation, tolerance, and cognitive disruption. Positive allosteric modulators (PAMs) of the GABA(B) receptor may have similar therapeutic effects as agonists with superior side-effect profiles. The present study behaviorally characterized N-([1R,2R,4S]-bicyclo[2.2.1]hept-2-yl)-2-methyl-5-(4-[trifluoromethyl]phenyl)-4-pyrimidinamine (BHF177), a GABA(B) receptor PAM, in mouse models of anxiety-like behavior, learning and memory. In addition, the effects of BHF177 were compared with the agonist baclofen. Unlike the anxiolytic chlordiazepoxide, baclofen (0.5, 1.5, and 2.5 mg/kg, intraperitoneally) and BHF177 (10, 20, and 40 mg/kg, orally) had no effect on anxiety-like behavior in the elevated plus maze, light/dark box, or Vogel conflict test. Baclofen increased punished drinking in the Vogel conflict test, but this effect may be attributable to the analgesic actions of baclofen. At the highest dose tested (2.5 mg/kg), baclofen-treated mice exhibited sedation-like effects (i.e., reduced locomotor activity) across many of the tests, whereas BHF177-treated mice exhibited no sedation-like effects. BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific. At doses that were not sedative or pro-convulsant, baclofen and BHF177 had no selective effects on fear memory retrieval in contextual and cued fear conditioning or spatial learning and memory in the Barnes maze. These data suggest that BHF177 has little sedative activity, no anxiolytic-like profile, and minimal impairment of learning and memory in mice. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:156 / 167
页数:12
相关论文
共 50 条
  • [1] The GABAB receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats
    Li, Xia
    Kaczanowska, Katarzyna
    Finn, M. G.
    Markou, Athina
    Risbrough, Victoria B.
    NEUROPHARMACOLOGY, 2015, 97 : 357 - 364
  • [2] Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior
    Partyka, Anna
    Klodzinska, Aleksandra
    Szewczyk, Bernadeta
    Wieronska, Joanna M.
    Chojnacka-Wojcik, Ewa
    Librowski, Tadeusz
    Filipek, Barbara
    Nowak, Gabriel
    Pilc, Andrzej
    PHARMACOLOGICAL REPORTS, 2007, 59 (06) : 757 - 762
  • [3] Reduction of Alcohol's Reinforcing and Motivational Properties by the Positive Allosteric Modulator of the GABAB Receptor, BHF177, in Alcohol-Preferring Rats
    Maccioni, Paola
    Carai, Mauro A. M.
    Kaupmann, Klemens
    Guery, Sebastien
    Froestl, Wolfgang
    Leite-Morris, Kimberly A.
    Gessa, Gian Luigi
    Colombo, Giancarlo
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2009, 33 (10) : 1749 - 1756
  • [4] Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783 -: Comparison with the effect of the GABAB receptor direct agonist, baclofen
    Maccioni, Paola
    Fantini, Noemi
    Froestl, Wolfgang
    Carai, Mauro A. M.
    Gessa, Gian Luigi
    Colombo, Giancarlo
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2008, 32 (09) : 1558 - 1564
  • [5] Effects of GABAB receptor positive allosteric modulator BHF177 and IRS-1 on apoptosis of hippocampal neurons in rats with refractory epilepsy via the PI3K/Akt pathway
    Wang, Peng
    Nan, Shanji
    Zhang, Yizhi
    Fan, Jia
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (11) : 1775 - 1786
  • [6] The GABAB Receptor-Positive Modulator GS39783 and the GABAB Receptor Agonist Baclofen Attenuate the Reward-Facilitating Effects of Cocaine: Intracranial Self-Stimulation Studies in the Rat
    David A Slattery
    Athina Markou
    Wolfgang Froestl
    John F Cryan
    Neuropsychopharmacology, 2005, 30 : 2065 - 2072
  • [7] Effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on the development and expression of amphetamine-induced locomotor sensitization in rats
    Laura N. Cedillo
    Florencio Miranda
    Pharmacological Reports, 2013, 65 : 1132 - 1143
  • [8] Effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on the development and expression of amphetamine-induced locomotor sensitization in rats
    Cedillo, Laura N.
    Miranda, Florencio
    PHARMACOLOGICAL REPORTS, 2013, 65 (05) : 1132 - 1143
  • [9] The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine:: Intracranial self-stimulation studies in the rat
    Slattery, DA
    Markou, A
    Froestl, W
    Cryan, JF
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (11) : 2065 - 2072
  • [10] Discriminative Stimulus Effects of the GABAB Receptor-Positive Modulator rac-BHFF: Comparison with GABAB Receptor Agonists and Drugs of Abuse
    Koek, Wouter
    Cheng, Kejun
    Rice, Kenner C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 344 (03): : 553 - 560